Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective vigilantly but unsuccessfully to create a single therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of the past several shares of mine. My first CytoDyn post, “CytoDyn: What To Do When It’s Too Good to be able to Be True?”, set out all of the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such a highly promotional image in the Uptick Newswire interview that I came away with an inadequate impression of the company.

Irony of irony, the poor impression of mine of the company has grown steadily, although the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger at the moment still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the treatment and prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the expertise and associated intellectual property from Progenics to CytoDyn, and also approximately twenty five million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 million) and also the first brand new drug program approval ($5 million), and even royalty payments of 5 % of net sales upon commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with multiple therapies and many indications, it has this single therapy as well as a “broad pipeline of indications” since it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely advantageous therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an energetic company with diverse interests albeit focused on leronlimab, several illness sorts, multiple publications in addition to multiple delivering presentations.

Could it all be smoke and mirrors? That is a question I have been asking myself with the really start of my interest in this particular business. Judging by the multiples of a huge number of diverse remarks on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m much from alone in this question.

CytoDyn is a classic battleground, or perhaps some might say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *